Skip to main content
Premium Trial:

Request an Annual Quote

Broad Institute to Use Affymetrix Arrays In Three Genomics Projects

NEW YORK, Sept. 22 (GenomeWeb News) - The Broad Institute of MIT and Harvard will use high-throughput microarray technology from Affymetrix in three studies involving RNA expression analysis, SNP genotyping, and DNA resequencing, Affymetrix said today.


In a genotyping study, researchers at the Broad Institute plan to use GeneChip SNP genotyping arrays to identify genes associated with common complex diseases. Affymetrix said it will make the arrays, which are based on the technology of its current Mapping 10K and Mapping 100K arrays, broadly available.


The institute's researchers also plan to conduct whole-genome RNA expression studies of several thousand samples, using GeneChip microarrays, and to assemble the results into a gene expression database of different physiological and disease conditions.


Finally, Broad Institute scientists plan to discover DNA sequence variations in cancer samples using CustomSeq resequencing arrays. They will also collaborate with Affymetrix to develop algorithms for automated sequence analysis.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.